Bioatla

Bioatla ROA

The Return on Assets (ROA) of Bioatla (BCAB) as of Nov 18, 2026 is -431.06 %. In the previous year, Return on Assets (ROA) was -133.10 % — a change of 223.85% (lower).

ROA

-431.06 %

YoY

223.85%

Last updated:

In 2025, Bioatla's return on assets (ROA) was -431.06 %, a 223.85% increase from the -133.10 % ROA in the previous year.

The Bioatla ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-174.18 USD
Jan 1, 2019
-319.13 USD
Jan 1, 2020
-14.64 USD
Jan 1, 2021
-37.50 USD
Jan 1, 2022
-46.64 USD
Jan 1, 2023
-103.18 USD
Jan 1, 2024
-133.10 USD
Jan 1, 2025
-431.06 USD
The Bioatla ROA history
YEARROAYoY
-431.06 %+223.85%
-133.10 %+29.00%
-103.18 %+121.22%
-46.64 %+24.38%
-37.50 %+156.17%
-14.64 %-95.41%
-319.13 %+83.21%
-174.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

ROA Details

Understanding Bioatla's Return on Assets (ROA)

Bioatla's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Bioatla's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Bioatla's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Bioatla’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Bioatla stock

Return on Assets (ROA) of Bioatla is -431.06 % in 2025.

Return on Assets (ROA) of Bioatla changed from -133.10 % to -431.06 %, representing a 223.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Bioatla since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Bioatla with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bioatla

All Key Metrics — Bioatla